| Ronald J Krajnik, MD | |
|
1405 Mill St, New London, WI 54961-2155 | |
| (920) 531-2021 | |
| Not Available |
| Full Name | Ronald J Krajnik |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Location | 1405 Mill St, New London, Wisconsin |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1225072184 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | 35701 (Wisconsin) | Primary |
| Entity Name | Thedacare Medical Center - Shawano, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1548260839 PECOS PAC ID: 5890605836 Enrollment ID: O20031117000117 |
News Archive
ZIOPHARM Oncology, Inc., a drug development company employing small molecule and synthetic biology approaches to cancer therapy, today announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food & Drug Administration (FDA) to begin clinical study of Ad-RTS-IL-12, a novel DNA-based therapeutic candidate.
BioSpace launched the 2011 BioForest™ Hotbed Campaign this morning, showcasing biotechnological, pharmaceutical and medical device companies across the United States and Canada.
News-Medical speaks to Dr. Natalia Freund about her latest research into COVID-19, and how most people are capable of producing neutralizing antibodies against the virus.
Researchers studying two generations of a family affected by pediatric acute lymphoblastic leukemia (ALL) have identified an inherited variation in the ETV6 gene that is associated with an increased risk of developing the disease. St. Jude Children's Research Hospital investigators led the study, which appears in the October 28 issue of the journal Lancet Oncology.
Comprehensive clinical genomic testing of an adolescent patient, including whole genome sequencing, helped researchers identify mutations in a single gene that drive the most common childhood melanoma.
› Verified 1 days ago
| Entity Name | Thedacare Medical Center - Berlin Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1760413777 PECOS PAC ID: 0446151666 Enrollment ID: O20040120000214 |
News Archive
ZIOPHARM Oncology, Inc., a drug development company employing small molecule and synthetic biology approaches to cancer therapy, today announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food & Drug Administration (FDA) to begin clinical study of Ad-RTS-IL-12, a novel DNA-based therapeutic candidate.
BioSpace launched the 2011 BioForest™ Hotbed Campaign this morning, showcasing biotechnological, pharmaceutical and medical device companies across the United States and Canada.
News-Medical speaks to Dr. Natalia Freund about her latest research into COVID-19, and how most people are capable of producing neutralizing antibodies against the virus.
Researchers studying two generations of a family affected by pediatric acute lymphoblastic leukemia (ALL) have identified an inherited variation in the ETV6 gene that is associated with an increased risk of developing the disease. St. Jude Children's Research Hospital investigators led the study, which appears in the October 28 issue of the journal Lancet Oncology.
Comprehensive clinical genomic testing of an adolescent patient, including whole genome sequencing, helped researchers identify mutations in a single gene that drive the most common childhood melanoma.
› Verified 1 days ago
| Entity Name | Thedacare Regional Medical Center - Appleton, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1902832306 PECOS PAC ID: 2163319039 Enrollment ID: O20040304000064 |
News Archive
ZIOPHARM Oncology, Inc., a drug development company employing small molecule and synthetic biology approaches to cancer therapy, today announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food & Drug Administration (FDA) to begin clinical study of Ad-RTS-IL-12, a novel DNA-based therapeutic candidate.
BioSpace launched the 2011 BioForest™ Hotbed Campaign this morning, showcasing biotechnological, pharmaceutical and medical device companies across the United States and Canada.
News-Medical speaks to Dr. Natalia Freund about her latest research into COVID-19, and how most people are capable of producing neutralizing antibodies against the virus.
Researchers studying two generations of a family affected by pediatric acute lymphoblastic leukemia (ALL) have identified an inherited variation in the ETV6 gene that is associated with an increased risk of developing the disease. St. Jude Children's Research Hospital investigators led the study, which appears in the October 28 issue of the journal Lancet Oncology.
Comprehensive clinical genomic testing of an adolescent patient, including whole genome sequencing, helped researchers identify mutations in a single gene that drive the most common childhood melanoma.
› Verified 1 days ago
| Entity Name | Thedacare Medical Center - New London, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1538127220 PECOS PAC ID: 5698664480 Enrollment ID: O20040311000254 |
News Archive
ZIOPHARM Oncology, Inc., a drug development company employing small molecule and synthetic biology approaches to cancer therapy, today announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food & Drug Administration (FDA) to begin clinical study of Ad-RTS-IL-12, a novel DNA-based therapeutic candidate.
BioSpace launched the 2011 BioForest™ Hotbed Campaign this morning, showcasing biotechnological, pharmaceutical and medical device companies across the United States and Canada.
News-Medical speaks to Dr. Natalia Freund about her latest research into COVID-19, and how most people are capable of producing neutralizing antibodies against the virus.
Researchers studying two generations of a family affected by pediatric acute lymphoblastic leukemia (ALL) have identified an inherited variation in the ETV6 gene that is associated with an increased risk of developing the disease. St. Jude Children's Research Hospital investigators led the study, which appears in the October 28 issue of the journal Lancet Oncology.
Comprehensive clinical genomic testing of an adolescent patient, including whole genome sequencing, helped researchers identify mutations in a single gene that drive the most common childhood melanoma.
› Verified 1 days ago
| Entity Name | Thedacare Regional Medical Center-neenah Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1518993880 PECOS PAC ID: 8921090846 Enrollment ID: O20040401000148 |
News Archive
ZIOPHARM Oncology, Inc., a drug development company employing small molecule and synthetic biology approaches to cancer therapy, today announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food & Drug Administration (FDA) to begin clinical study of Ad-RTS-IL-12, a novel DNA-based therapeutic candidate.
BioSpace launched the 2011 BioForest™ Hotbed Campaign this morning, showcasing biotechnological, pharmaceutical and medical device companies across the United States and Canada.
News-Medical speaks to Dr. Natalia Freund about her latest research into COVID-19, and how most people are capable of producing neutralizing antibodies against the virus.
Researchers studying two generations of a family affected by pediatric acute lymphoblastic leukemia (ALL) have identified an inherited variation in the ETV6 gene that is associated with an increased risk of developing the disease. St. Jude Children's Research Hospital investigators led the study, which appears in the October 28 issue of the journal Lancet Oncology.
Comprehensive clinical genomic testing of an adolescent patient, including whole genome sequencing, helped researchers identify mutations in a single gene that drive the most common childhood melanoma.
› Verified 1 days ago
| Entity Name | Thedacare Medical Center - Waupaca, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1780782680 PECOS PAC ID: 3072504216 Enrollment ID: O20040524000645 |
News Archive
ZIOPHARM Oncology, Inc., a drug development company employing small molecule and synthetic biology approaches to cancer therapy, today announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food & Drug Administration (FDA) to begin clinical study of Ad-RTS-IL-12, a novel DNA-based therapeutic candidate.
BioSpace launched the 2011 BioForest™ Hotbed Campaign this morning, showcasing biotechnological, pharmaceutical and medical device companies across the United States and Canada.
News-Medical speaks to Dr. Natalia Freund about her latest research into COVID-19, and how most people are capable of producing neutralizing antibodies against the virus.
Researchers studying two generations of a family affected by pediatric acute lymphoblastic leukemia (ALL) have identified an inherited variation in the ETV6 gene that is associated with an increased risk of developing the disease. St. Jude Children's Research Hospital investigators led the study, which appears in the October 28 issue of the journal Lancet Oncology.
Comprehensive clinical genomic testing of an adolescent patient, including whole genome sequencing, helped researchers identify mutations in a single gene that drive the most common childhood melanoma.
› Verified 1 days ago
| Entity Name | Thedacare Medical Center - Wild Rose, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1043263999 PECOS PAC ID: 6507840923 Enrollment ID: O20040615000235 |
News Archive
ZIOPHARM Oncology, Inc., a drug development company employing small molecule and synthetic biology approaches to cancer therapy, today announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food & Drug Administration (FDA) to begin clinical study of Ad-RTS-IL-12, a novel DNA-based therapeutic candidate.
BioSpace launched the 2011 BioForest™ Hotbed Campaign this morning, showcasing biotechnological, pharmaceutical and medical device companies across the United States and Canada.
News-Medical speaks to Dr. Natalia Freund about her latest research into COVID-19, and how most people are capable of producing neutralizing antibodies against the virus.
Researchers studying two generations of a family affected by pediatric acute lymphoblastic leukemia (ALL) have identified an inherited variation in the ETV6 gene that is associated with an increased risk of developing the disease. St. Jude Children's Research Hospital investigators led the study, which appears in the October 28 issue of the journal Lancet Oncology.
Comprehensive clinical genomic testing of an adolescent patient, including whole genome sequencing, helped researchers identify mutations in a single gene that drive the most common childhood melanoma.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ronald J Krajnik, MD Po Box 8003, Appleton, WI 54912-8003 Ph: (920) 996-3298 | Ronald J Krajnik, MD 1405 Mill St, New London, WI 54961-2155 Ph: (920) 531-2021 |
News Archive
ZIOPHARM Oncology, Inc., a drug development company employing small molecule and synthetic biology approaches to cancer therapy, today announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food & Drug Administration (FDA) to begin clinical study of Ad-RTS-IL-12, a novel DNA-based therapeutic candidate.
BioSpace launched the 2011 BioForest™ Hotbed Campaign this morning, showcasing biotechnological, pharmaceutical and medical device companies across the United States and Canada.
News-Medical speaks to Dr. Natalia Freund about her latest research into COVID-19, and how most people are capable of producing neutralizing antibodies against the virus.
Researchers studying two generations of a family affected by pediatric acute lymphoblastic leukemia (ALL) have identified an inherited variation in the ETV6 gene that is associated with an increased risk of developing the disease. St. Jude Children's Research Hospital investigators led the study, which appears in the October 28 issue of the journal Lancet Oncology.
Comprehensive clinical genomic testing of an adolescent patient, including whole genome sequencing, helped researchers identify mutations in a single gene that drive the most common childhood melanoma.
› Verified 1 days ago
James John Macneal, DO Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1405 Mill St, New London, WI 54961 Phone: 920-531-2030 Fax: 920-531-2016 | |
Shawn S Williamson, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1405 Mill St, New London, WI 54961 Phone: 920-531-2021 | |
Joseph R James, DO Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1405 Mill St, New London, WI 54961 Phone: 920-531-2000 | |
Amber Lievens Widenski, D.O. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1405 Mill St, New London, WI 54961 Phone: 920-531-2030 | |
Jocko R Zifferblatt, D.O. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1405 Mill St, New London, WI 54961 Phone: 920-531-2000 | |
Dr. John A Watring, D.O. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1405 Mill St, New London, WI 54961 Phone: 920-531-2000 |